A future study comparing SGLT-2 inhibitors with acetazolamide in a head-to-head trial that compares short-term and long-term outcomes would shed light possibly on why two diuretics with similar mechanisms have benefits in different intervals of heart failure. The gene discussed is SLC5A2; the disease is heart failure.